Investor List:

Top Pharmaceuticals Series A Investors in Raleigh-Durham / Southeast US (29)

Know someone who's actively diligencing and investing? Add them to this list.
About this list
We’ve compiled a list of the top Pharmaceuticals investors. The goal is to help Founders find the best investors to target and get introduced to.
Photo of Eric Toone, Managing Director at Breakthrough Energy Ventures
Eric Toone
Breakthrough Energy Ventures·Managing Director
Sweet spot: $25.0M
Range: $500K - $50.0M
Investors in Durham (NC)
Photo of Mike Dial, Partner at Hatteras Venture Partners
Mike Dial
Sweet spot: $2.0M
Range: $400K - $4.0M
Investors in Durham (NC), Investors in Raleigh-Durham / Southeast US
Photo of Stephen Romanoff, Investor at Sweater Ventures
Stephen Romanoff
Sweet spot: $2.0M
Range: $50K - $5.0M
Investors in San Francisco (CA), Investors in New York (NY), Investors in Atlanta (GA)
Investors in Pharmaceuticals (Series B), Investors in AR/VR (Series B), Investors in Space (Series B), Investors in ClimateTech/CleanTech (Series B), Investors in Pharmaceuticals (Series A), Investors in Data Services (Series B), Investors in AgTech (Series B), Investors in Pharmaceuticals (Seed), Investors in AR/VR (Series A), Investors in EnergyTech (Series B), Investors in AgTech (Series A), Investors in Space (Series A), Investors in Data Services (Series A), Investors in Space (Seed), Investors in EnergyTech (Series A), Investors in SaaS (Series B), Investors in ClimateTech/CleanTech (Series A), Investors in AgTech (Series B), Investors in EnergyTech (Seed), Investors in AR/VR (Seed), Investors in Pharmaceuticals (Series B), Investors in Enterprise (Series B), Investors in AgTech (Seed), Investors in Space (Series B), Investors in EnergyTech (Series B), Investors in AI (Series B), Investors in ClimateTech/CleanTech (Seed), Investors in Data Services (Seed), Investors in AR/VR (Series B), Investors in Pharmaceuticals (Series B), Investors in Space (Series B), Investors in Space (Series A), Investors in ClimateTech/CleanTech (Series B), Investors in Enterprise (Series A), Investors in Space (Seed), Investors in SaaS (Series A), Investors in AR/VR (Series B), Investors in AgTech (Series B), Investors in Pharmaceuticals (Seed), Investors in AR/VR (Series A), Investors in Pharmaceuticals (Series A), Investors in AgTech (Series A), Investors in EnergyTech (Series A), Investors in AI (Series A), Investors in EnergyTech (Seed), Investors in Enterprise (Seed), Investors in EnergyTech (Series B), Investors in AR/VR (Seed), Investors in AgTech (Seed), Investors in SaaS (Seed), Investors in Pharmaceuticals (Seed), Investors in AI (Seed), Investors in Pharmaceuticals (Series A), Investors in Space (Series B), Investors in Data Services (Series B), Investors in Space (Series A), Investors in Pharmaceuticals (Series B), Investors in ClimateTech/CleanTech (Series B), Investors in ClimateTech/CleanTech (Series A), Investors in AR/VR (Series A), Investors in AgTech (Series A), Investors in AR/VR (Series B), Investors in Space (Seed), Investors in AgTech (Series B), Investors in AgTech (Seed), Investors in EnergyTech (Series A), Investors in AR/VR (Seed), Investors in Data Services (Series B), Investors in Data Services (Series A), Investors in Data Services (Seed), Investors in ClimateTech/CleanTech (Seed), Investors in EnergyTech (Seed), Investors in EnergyTech (Series B), Investors in AI (Series B), Investors in Space (Series A), Investors in Enterprise (Series B), Investors in Pharmaceuticals (Series A), Investors in Pharmaceuticals (Seed), Investors in SaaS (Series B), Investors in AR/VR (Series A), Investors in ClimateTech/CleanTech (Series B), Investors in ClimateTech/CleanTech (Series A), Investors in Space (Seed), Investors in Data Services (Series A), Investors in AgTech (Series A), Investors in Data Services (Seed), Investors in AI (Series A), Investors in Data Services (Series B), Investors in AR/VR (Seed), Investors in ClimateTech/CleanTech (Seed), Investors in AI (Seed), Investors in EnergyTech (Series A), Investors in AI (Series B), Investors in SaaS (Series A), Investors in AgTech (Seed), Investors in Enterprise (Series A), Investors in SaaS (Seed), Investors in EnergyTech (Seed), Investors in SaaS (Series B), Investors in Enterprise (Seed), Investors in Data Services (Series A), Investors in ClimateTech/CleanTech (Series A), Investors in Enterprise (Series B), Investors in Data Services (Seed), Investors in AI (Series A), Investors in AI (Series B), Investors in SaaS (Series A), Investors in ClimateTech/CleanTech (Seed), Investors in SaaS (Series B), Investors in AI (Seed), Investors in SaaS (Seed), Investors in Enterprise (Series B), Investors in Enterprise (Series A), Investors in Raleigh-Durham / Southeast US (Other Lists), Investors in Enterprise (Seed), Investors in AI (Series A), Investors in SaaS (Series A), Investors in AI (Seed), Investors in Enterprise (Series A), Investors in SaaS (Seed), Investors in Diverse Investors (Other Lists), Investors in Enterprise (Seed), Investors in Investors who invested in diverse founders (Other Lists), Investors in New York City (Other Lists), Investors in San Francisco Bay Area (Other Lists)
Photo of David Pierson, Managing Director at Syngenta Group Ventures
David Pierson
Syngenta Group Ventures·Managing Director
Sweet spot: $1.5M
Range: $100K - $5.0M
Investors in Durham (NC)
Investors in Pharmaceuticals (Series A), Investors in Pharmaceuticals (Series B), Investors in BioTech (Series B), Investors in AgTech (Series B), Investors in E-commerce (Series B), Investors in E-commerce (Series A), Investors in AgTech (Series A), Investors in Pharmaceuticals (Seed), Investors in AgTech (Seed), Investors in BioTech (Series A), Investors in E-commerce (Seed), Investors in BioTech (Seed), Investors in AgTech (Series B), Investors in Pharmaceuticals (Series B), Investors in AgTech (Series A), Investors in Raleigh-Durham / Southeast US (Other Lists), Investors in Pharmaceuticals (Series A), Investors in E-commerce (Series B), Investors in BioTech (Series B), Investors in AgTech (Seed), Investors in Pharmaceuticals (Seed), Investors in E-commerce (Series A), Investors in BioTech (Series A), Investors in E-commerce (Seed), Investors in BioTech (Seed)
Photo of Matt Hughes, Managing Director at Allele Capital Partners
Matt Hughes
Allele Capital Partners·Managing Director
Sweet spot: $1.5M
Range: $100K - $5.0M
Investors in Boca Raton (FL)
Investors in Pharmaceuticals (Series B), Investors in Pharmaceuticals (Series A), Investors in BioTech (Series B), Investors in Pharmaceuticals (Seed), Investors in FinTech (Series B), Investors in BioTech (Series A), Investors in BioTech (Seed), Investors in FinTech (Seed), Investors in FinTech (Series A), Investors in Pharmaceuticals (Series B), Investors in Pharmaceuticals (Seed), Investors in Pharmaceuticals (Series A), Investors in BioTech (Series B), Investors in Raleigh-Durham / Southeast US (Other Lists), Investors in BioTech (Series A), Investors in BioTech (Seed), Investors in FinTech (Series B), Investors in FinTech (Series A), Investors in FinTech (Seed)
Photo of Kenneth Lee, General Partner at Hatteras Venture Partners
Kenneth Lee
Hatteras Venture Partners·General Partner
Sweet spot: $1.5M
Range: $100K - $5.0M
Investors in Durham (NC)
Photo of C. Bradford Kelly, Managing Director at Spur Capital Partners
C. Bradford Kelly
Spur Capital Partners·Managing Director
Sweet spot: $1.5M
Range: $100K - $5.0M
Photo of Clay Thorp, General Partner at Hatteras Venture Partners
Clay Thorp
Hatteras Venture Partners·General Partner
Sweet spot: $1.5M
Range: $100K - $5.0M
Investors in Chapel Hill (NC)
Investors in Diagnostics (Series A), Investors in Diagnostics (Seed), Investors in Medical Devices (Seed), Investors in Medical Devices (Series A), Investors in Pharmaceuticals (Series A), Investors in Pharmaceuticals (Seed), Investors in BioTech (Series A), Investors in BioTech (Seed), Investors in Diagnostics (Seed), Investors in Diagnostics (Series A), Investors in Raleigh-Durham / Southeast US (Other Lists), Investors in Medical Devices (Seed), Investors in Pharmaceuticals (Series A), Investors in Medical Devices (Series A), Investors in Pharmaceuticals (Seed), Investors in BioTech (Series A), Investors in BioTech (Seed)